GSK plc — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
11-K
13F-HR
20-F
20-F/A
25-NSE
3
3/A
4
4/A
424B2
424B3
5
6-K
6-K/A
8-A12B
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3/A
F-3ASR
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
POS AM
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G/A
SD
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002851 | Mar 27, 2026 | — |
| 6-K | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA | 0001654954-26-002848 | Mar 27, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002780 | Mar 26, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002744 | Mar 25, 2026 | — |
| 6-K | NOTICE OF AGM | 0001654954-26-002728 | Mar 25, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002709 | Mar 25, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002641 | Mar 24, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002600 | Mar 23, 2026 | — |
| 6-K | ADMISSION TO TRADING | 0001654954-26-002596 | Mar 23, 2026 | — |
| 6-K | GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS | 0001654954-26-002580 | Mar 23, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002577 | Mar 23, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002514 | Mar 20, 2026 | — |
| 6-K | LYNAVOY (LINERIXIBAT) APPROVED BY US FDA | 0001654954-26-002482 | Mar 19, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002466 | Mar 19, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002367 | Mar 18, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002356 | Mar 18, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002324 | Mar 17, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002311 | Mar 17, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002266 | Mar 16, 2026 | — |
| 6-K | US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR | 0001654954-26-002214 | Mar 13, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002208 | Mar 13, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-002183 | Mar 12, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002166 | Mar 12, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002120 | Mar 11, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002076 | Mar 10, 2026 | — |
| 6-K | BOARD COMMITTEE CHANGE | 0001654954-26-002019 | Mar 9, 2026 | — |
| 6-K | GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS | 0001654954-26-002008 | Mar 9, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-002005 | Mar 9, 2026 | — |
| 6-K | FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F | 0001654954-26-001975 | Mar 6, 2026 | — |
| IRANNOTICE | IRANNOTICE | 0001131399-26-000006 | Mar 6, 2026 | — |
| 20-F | 20-F | 0001131399-26-000004 | Mar 6, 2026 | Dec 31, 2025 |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001950 | Mar 6, 2026 | — |
| 6-K | GSK PUBLISHES ANNUAL REPORT 2025 | 0001654954-26-001917 | Mar 5, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001907 | Mar 5, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001860 | Mar 4, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001852 | Mar 4, 2026 | — |
| 6-K | GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS | 0001654954-26-001801 | Mar 3, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001790 | Mar 3, 2026 | — |
| SC TO-T/A | SC TO-T/A | 0001193125-26-086527 | Mar 3, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001756 | Mar 2, 2026 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-26-001733 | Mar 2, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001650 | Feb 27, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001625 | Feb 27, 2026 | — |
| 6-K | LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA | 0001654954-26-001580 | Feb 26, 2026 | — |
| 6-K | BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW | 0001654954-26-001578 | Feb 26, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001575 | Feb 26, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001551 | Feb 25, 2026 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001547 | Feb 25, 2026 | — |
| 6-K | GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA | 0001654954-26-001533 | Feb 25, 2026 | — |
| 6-K | TRANSACTION IN OWN SHARES | 0001654954-26-001531 | Feb 25, 2026 | — |